Guardant Health (GH) investors have a new number to think about this week.
Bernstein SocGen Group raised its price target on the cancer-screening company’s stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intact.
The new price target came less than a day after a major insurance decision boosted the outlook for Guardant’s blood-based colorectal cancer test.
UnitedHealth (UNH) Group, the nation’s largest health insurer, has agreed to cover Shield as a first-line screening option for millions of members aged 45 and older. Shield is Guardant’s leading cancer screening test.
That single decision from UNH unlocked a market that Wall Street wasn’t expecting for the next few years.
Guardant shares already jumped nearly 20% in the week following the news and now trade close to their 52-week high.
Here’s what changed, and what investors watching the stock should know now.
Guardant Health stock rallies as Bernstein doubles down on Shield
According to Investing.com, Bernstein analyst Eve Burstein raised her price target on Guardant Health to $200 from $175 on July 2, maintaining an Outperform rating.
The upgrade followed UnitedHealth’s decision to cover Shield for members ages 45 to 75, matching Medicare’s existing coverage terms.
Bernstein estimates the move gives Guardant access to 10 million newly reimbursed customers.
That single-payer decision carries enormous weight. Bernstein pointed to past coverage patterns for Guardant360 and Exact Sciences’ Cologuard.
Bernstein noted that once one major insurer commits, others tend to follow within a matter of quarters.
The math behind the new target is interesting.
Bernstein nearly doubled its 2030 revenue estimate for Shield from $770 million to about $1.5 billion. It also raised its 2040 estimate to approximately $4.1 billion.
A blood-based screening test like Guardant Health’s Shield is now covered by UnitedHealth for millions of members aged 45 and older
Why UnitedHealth’s coverage decision reshapes Guardant Health’s growth math
Shield is a blood test that screens average-risk adults who are 45 and older for colorectal cancer. It is an alternative to colonoscopies and at-home stool kits. A single blood draw is all it takes.
UnitedHealth’s decision matters because commercial insurers, not just Medicare, now cover more patients.
TD Cowen estimates the move could expand Shield’s reimbursable market by about 17%, based on 10.5 million UnitedHealth members ages 45 to 64.
More Healthcare Stocks:
- JPMorgan resets UnitedHealth stock target for 2026
- Jim Cramer turns bullish on health care stock after years of doubt
- Morgan Stanley sees writing on wall for key drug research stocks
The UnitedHealth win wasn’t the only good news for GH.
According to a Guardant release, the FDA approved an expanded Guardant360 Liquid CDx panel in May, assessing a far wider range of genes than the prior version.
Weeks later, the American Cancer Society noted the inclusion of Shield in its official screening guidelines.
Related: Eli Lilly scores a first in major pharma milestone
Guardant also graduated into the Russell 1000 during June’s index reconstitution, LSEG reported.
According to Guardant, co-CEO AmirAli Talasaz said the American Cancer Society’s decision to add Shield to its guidelines marks “a momentous step forward in our collective work” to reach unscreened patients.
What could derail Guardant Health’s rally from here
Even bulls see some risk in the stock. According to Investing.com, their fair-value model still considers Guardant Health overvalued relative to its underlying fundamentals.
The company’s trailing 12-month loss per share sits at $3.40, and its net margin remains deeply negative, according to Yahoo Finance data.
According to Simply Wall St, company insiders have also been net sellers of the stock over the past year, collectively offloading more than they bought.
Competition also remains real. Exact Sciences’ Cologuard still leads at-home stool-based screening.
The American Cancer Society also notes that blood-based tests catch early-stage cancers less reliably than stool-based ones.
What Guardant Health investors should watch next
The bigger prize is still ahead. BTIG and TD Cowen both expect additional commercial insurers to follow UnitedHealth’s lead over the coming quarters.
A formal recommendation from the U.S. Preventive Services Task Force would open the door even wider, though Bernstein says that was already part of its long-term assumptions.
Guardant’s next earnings report is expected around July 29, 2026, according to Yahoo Finance.
For readers considering a position, the stock has already priced in a lot of good news after roughly quadrupling in value since its June drop.
Catalysts that could move Guardant Health further:
- Additional commercial insurers following UnitedHealth’s coverage decision.
- Guardant’s second-quarter earnings report, expected around July 29, 2026.
- Progress toward a formal USPSTFrecommendation for blood-based screening.
- Continued index-driven buying tied to Guardant’s new membership in the Russell 1000.
Related: Morgan Stanley sees writing on wall for key drug research stocks